GLP-1s and Breast Cancer: Navigating the Link Between Weight and Risk

The emergence of data linking glucagon-like peptide-1 (GLP-1) receptor agonists to a lower incidence of breast cancer has sparked significant interest across the oncology community. While observational studies, such as recent findings from Pennsylvania State University, suggest a protective benefit, clinical experts urge a nuanced interpretation of the results.

In a recent interview, Loren Rourke, MD, a board-certified breast cancer surgeon, women’s health advocate and author, discussed the biological mechanisms behind these findings and the practical implications for oncology nursing practice.

The biological nexus: Estrogen and inflammation

The correlation between GLP-1 use and reduced breast cancer risk is rooted in established metabolic pathways. Rourke emphasized that for patients with hormone receptor-positive disease, the relationship between adipose tissue and estrogen production is a primary factor.

"We make estrogen in our fat," Dr. Rourke noted. "If [patients] have a higher BMI, they are naturally making more estrogen in their fat tissue, so it is very logical to think that GLP-1s … are going to have an extra benefit, a secondary benefit of helping the situation with breast cancer."

Beyond hormonal influence, the impact of GLP-1s on systemic inflammation and glucose regulation plays a critical role. GLP-1 agonists stimulate insulin secretion and lower blood glucose levels, addressing the chronic inflammation often seen in patients with type 2 diabetes.

"We know cancer doesn't do well in a chronically inflamed environment," Rourke explained. "These drugs [lower inflammation] ... and they’re also lowering the patient’s BMI, which is lowering their fat. So all of this makes logical sense."

Risk reduction vs. primary prevention

While the data is promising, Rourke cautions that it is premature to categorize GLP-1s as primary prevention tools for breast cancer. Current research is largely retrospective, and randomized controlled trials are necessary to determine if the benefit is a direct molecular interaction or a secondary effect of weight loss.

"What we need to figure out is, is that risk reduction related only to obesity reduction, meaning we have less fat, less estrogen ... or is it actually something molecular happening at a drug interaction level that has an independent relationship with breast cancer?" Rourke said.

Clinical implications for oncology nurses

Oncology nurses and navigators are often the first point of contact for patients inquiring about new clinical data. When patients ask about starting a GLP-1 specifically for cancer risk reduction, Rourke suggests a supportive but evidence-based approach.

"I would say the first thing that they need to say is that this new data is promising, that it actually makes sense," Rourke advised. She encouraged nurses to assess the patient’s metabolic profile.

The perimenopausal transition represents a particularly challenging window for weight management. For these patients, Rourke suggested that GLP-1s may be a valuable adjunct to traditional lifestyle interventions. "Menopause is a real mountain to climb," she noted. "There may be a role for you to get on a GLP-1. I don't think it's anything to be ashamed of, and if it certainly can't hurt if it's used under the current guidelines and indications."

Impact on surgical and reconstructive outcomes

In the surgical setting, a patient’s metabolic health and BMI directly influence treatment options and recovery. High BMI can limit reconstructive choices following mastectomy, a reality Rourke described as "heartbreaking" for both the patient and the surgical team.

"If the obesity is significant, then oftentimes their options are limited in reconstruction," Rourke stated. "Some of the surgeries that [reconstruction surgeons] have to perform, if you cross a certain threshold in BMI, it can be absolutely dangerous."

Furthermore, obesity and poorly managed diabetes are significant risk factors for post-operative complications. "Wound healing is a problem oftentimes when people are morbidly obese or super obese, diabetes is at play, right? And that the tissue quality is not as good," Rourke explained.

Integrating GLP-1 therapies into a staged surgical plan may offer a pathway to improved outcomes. By connecting patients with bariatric specialists or initiating a GLP-1 regimen, clinicians can help patients improve their physical health prior to complex reconstructive procedures.

Looking ahead

As the oncology community awaits results from prospective, randomized controlled studies, the current data serves as a reinforcement of the importance of metabolic health in the breast cancer continuum. For oncology nurses, this involves balancing the excitement of new pharmacotherapy with the steady work of patient education and holistic wellness advocacy

"We're going to get the answer," Rourke concluded. "We just have to wait a little longer."